Last updated: February 19, 2026
What is Ansaid?
Ansaid, the brand name for flurbiprofen, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. It is available in both oral and ophthalmic formulations. The oral formulation is prescribed for conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. The ophthalmic solution is used to inhibit intraoperative miosis during cataract surgery and to manage postoperative inflammation following ocular surgery. Flurbiprofen is a propionic acid derivative and works by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins, which are mediators of pain and inflammation.
Patent Landscape and Exclusivity
The original U.S. patent for flurbiprofen, U.S. Patent No. 3,755,427, was filed by The Boots Company PLC on October 29, 1971, and issued on August 28, 1973. This patent covered the compound and its pharmaceutical use. The term of this patent has long expired, allowing for generic competition.
- Oral Formulations: Generic versions of Ansaid oral tablets are widely available. The primary market driver for these formulations is physician prescription and patient out-of-pocket cost compared to branded products. The active ingredient is readily manufactured, and no significant new process patents appear to be currently protecting the bulk drug production in a way that limits broad generic entry.
- Ophthalmic Formulations: The ophthalmic solution, often marketed as Ocufen or Flurbiprofen Ophthalmic Solution, also faces generic competition. Patents related to specific ophthalmic formulations or delivery systems might have existed, but the core active pharmaceutical ingredient (API) patent has expired. The market for ophthalmic NSAIDs is competitive, with several other drugs like ketorolac tromethamine and nepafenac offering alternatives for similar indications.
Market Performance and Sales Data
As a mature drug with expired foundational patents, Ansaid's market performance is largely dictated by the generic market and its positioning against alternative NSAIDs and other pain management therapies. Specific, publicly available sales data for branded Ansaid oral tablets is scarce due to its long presence in the market and the prevalence of generic versions.
- Branded vs. Generic Market Share: The vast majority of Ansaid prescriptions are now filled with generic flurbiprofen. This is a common trajectory for drugs that have been on the market for decades and lack current patent protection or significant new indications. The financial trajectory is therefore characterized by a declining branded market share and a stable to declining overall revenue for the API itself, driven by price competition among generic manufacturers.
- Therapeutic Class Competition: Within the NSAID class, Ansaid competes with well-established drugs like ibuprofen, naproxen, diclofenac, and celecoxib. Newer NSAIDs, particularly COX-2 selective inhibitors, and non-NSAID pain relievers (e.g., acetaminophen, opioids, and non-pharmacological therapies) also represent significant competitive pressures.
- Ophthalmic Market Performance: The market for ophthalmic flurbiprofen is a niche segment within the broader ophthalmology market. Its sales are tied to the volume of specific surgical procedures. While it holds a position, it competes with other anti-inflammatory agents and newer modalities for post-operative care.
Pricing and Reimbursement
Pricing for Ansaid is predominantly driven by generic market dynamics.
- Generic Pricing: The pricing of generic flurbiprofen is highly competitive, with multiple manufacturers offering the product. Prices are typically set at significantly lower levels than the original branded product. This low price point is a key factor in its continued use, particularly in healthcare systems or for patients where cost is a primary consideration.
- Reimbursement: As a widely used NSAID, flurbiprofen is generally covered by most health insurance plans and government programs (e.g., Medicare, Medicaid). The formulary status and co-payment levels will vary by plan, but its generic availability ensures broad access. The ophthalmic formulation's reimbursement is tied to its specific medical indication in surgical settings.
Manufacturing and Supply Chain
The manufacturing of flurbiprofen API is a mature process. Key considerations for the supply chain include:
- API Production: Multiple chemical manufacturers globally produce flurbiprofen API. The synthesis is well-established, meaning production costs are relatively low for manufacturers with efficient processes. Supply chain stability is generally high due to the widespread availability of raw materials and multiple production sites.
- Formulation and Packaging: Pharmaceutical companies specializing in generic drug manufacturing handle the formulation of Ansaid oral tablets and ophthalmic solutions. This includes tablet compression, sterile filtration for ophthalmic solutions, and packaging. The market is characterized by a large number of generic players, leading to fragmented manufacturing and distribution.
- Regulatory Compliance: All manufacturers must adhere to Good Manufacturing Practices (GMP) and meet regulatory standards set by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Inspections and compliance audits are ongoing.
Future Outlook and Market Trends
The future trajectory of Ansaid is largely defined by its status as a mature, off-patent drug.
- Continued Generic Dominance: Branded Ansaid oral tablets will likely continue to see minimal market presence. The market will remain dominated by generic flurbiprofen.
- Niche Ophthalmic Use: The ophthalmic formulation will continue to serve its specific indications in surgical settings. Its market share in this segment is unlikely to see significant growth without new clinical data supporting expanded uses or formulation improvements that confer a specific advantage.
- Competition and Innovation: The broader pain management and inflammation market is characterized by continuous innovation. Newer drug classes, biologics, and advanced therapeutic approaches may gradually erode the market share of older NSAIDs for certain patient populations or indications. However, the low cost of generic flurbiprofen ensures its continued use in situations where efficacy is sufficient and cost is a primary driver.
- Potential for Repurposing or New Formulations (Low Likelihood): While theoretically possible, the development of new, patented formulations or significant repurposing of flurbiprofen for novel indications is unlikely given its long history and the availability of more advanced therapeutic options. The investment required for such development would face significant hurdles in achieving patentable exclusivity and market differentiation against established and emerging treatments.
Key Takeaways
- Ansaid (flurbiprofen) is a mature NSAID with expired foundational patents, leading to widespread generic availability for both oral and ophthalmic formulations.
- The branded Ansaid market is negligible; the financial performance is now driven by the highly competitive generic flurbiprofen market.
- Pricing is dictated by generic competition, resulting in low-cost accessibility.
- The drug faces significant competition from other NSAIDs, COX-2 inhibitors, and alternative pain management therapies.
- The ophthalmic formulation retains a niche position in surgical care, competing with other anti-inflammatory agents.
- The future outlook is characterized by continued generic dominance and a stable, albeit modest, role in its established indications, with limited potential for significant growth or new patent-driven market expansion.
Frequently Asked Questions
What is the current patent status of Ansaid?
The original patent for flurbiprofen has expired. There are no significant new patents that prevent the broad manufacture and sale of generic flurbiprofen oral tablets or ophthalmic solutions.
How does Ansaid's market performance compare to other NSAIDs?
Ansaid's market performance is that of a mature generic drug. It does not command the market share or pricing power of newer NSAIDs or branded drugs with ongoing exclusivity periods. Its usage is primarily driven by cost-effectiveness.
Are there any new indications for Ansaid being explored?
There is no significant public information or clinical trial data indicating active research into new indications for flurbiprofen that would lead to new patentable applications.
What are the primary drivers of generic flurbiprofen sales?
The primary drivers are physician prescription based on established efficacy, patient preference for lower-cost medication, and healthcare system formularies that favor generic options.
What is the typical pricing structure for generic Ansaid?
Generic flurbiprofen is priced very competitively. Pricing is typically on a per-milligram or per-unit basis and is significantly lower than the original branded Ansaid, reflecting the crowded generic market.
What is the role of Ansaid in the ophthalmic market?
Ansaid ophthalmic solution is used to prevent miosis during cataract surgery and to manage postoperative inflammation. It competes with other topical NSAIDs and corticosteroids in this surgical setting.
Cited Sources
[1] U.S. Patent No. 3,755,427. (1973, August 28). Pharmaceutical compositions containing 2-(2-fluoro-4-biphenylyl)propionic acid. The Boots Company PLC.
